Malin streamlines portfolio to focus on developing four key investments
Brokers react positively to biotech firm’s new strategy
Malin, the drug and biotech company, has said it will have sufficient cash to follow its money on key investments.
The company is slimming down its portfolio of 18 investments to focus on four potentially valuable companies.
Malin’s chief financial officer Darragh Lyons told The Sunday Business Post that while there might be requirements for these companies to raise more money, Malin would be able to meet its commitments through its existing cash, ...
